Drugs / 177Lu HTK03170
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05570994 | Jan 2024 → Dec 2026 expected | castration-resistant prostate carcinoma, metastatic prostate carcinoma | British Columbia Cancer Agency | Enrolling by invitation | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu HTK03170 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05570994 ↗ |
| Known as | [177Lu]Lu-HTK03170 | “Prostate-specific membrane antigen (PSMA)-targeting radiopharmaceuticals, such as the novel [177Lu]Lu-HTK03170, present a promising therapeutic option for metastatic...” PMID 40306965 ↗ Jul 2025 |
| Modality | Other / unclassified | “Prostate-specific membrane antigen (PSMA)-targeting radiopharmaceuticals, such as the novel [177Lu]Lu-HTK03170” PMID 40306965 ↗ Jul 2025 |
| Route | Intravenous | “the administered activity will be 1.1 GBq ± 10% as an intravenous infusion over a time of 10 to 30 minutes” NCT05570994 ↗ |